Upcoming webinar: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?


E2di2R_XMAA02Cl.jpgRedenlab CSO, Adam Vogel, will be presenting at the upcoming joint webinar with the European Reference Network for rare or low prevalence complex diseases, Neurological Diseases (ERN-RND), Neuromuscular Dieseases (ERN EURO-NMD), and European Academy of Neurology. The subject of the webinar is Speech as a biomarker in Ataxia: What can it tell us & how should we use it. Sign up here!

Related Post

Redenlab awarded $2.5M to scale AI-driven speech biomarkers for dementia detection 

  • Posted on 29 September, 2025
    MEDIA RELEASE MELBOURNE, VIC – We’re pleased to share that Redenlab has been awarded $2.5 million in non-dilutive funding through...
    Read more

    Redenlab contributes to position paper on advancing digital healthtechnologies for frontotemporal degeneration

    • Posted on 15 May, 2025
      MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the...
      Read more

      Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research

      • Posted on 11 December, 2024
        MEDIA RELEASE Melbourne - December 2024 – Redenlab, a leader in innovative healthcare solutions, has partnered with the Queensland Institute of Medical...
        Read more